vs
Global Payments（GPN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Global Payments的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Global Payments净利率更高（16.4% vs 12.7%，领先3.6%），Revvity同比增速更快（5.9% vs -47.1%），Global Payments自由现金流更多（$347.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -25.9%）
Global Payments Inc.是美国跨国金融科技企业，面向商户、发卡机构及消费者提供支付技术与相关服务，支持信用卡、借记卡、数字支付及非接触式支付的交易处理，2021年6月入选《财富》500强榜单。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GPN vs RVTY — 直观对比
营收规模更大
GPN
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出53.0%
-47.1%
净利率更高
GPN
高出3.6%
12.7%
自由现金流更多
GPN
多$185.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
-25.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $217.5M | $98.4M |
| 毛利率 | 89.7% | — |
| 营业利润率 | 5.9% | 14.5% |
| 净利率 | 16.4% | 12.7% |
| 营收同比 | -47.1% | 5.9% |
| 净利润同比 | -61.6% | 3.9% |
| 每股收益（稀释后） | $0.91 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GPNRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $2.0B | $698.9M | ||
| Q2 25 | $2.0B | $720.3M | ||
| Q1 25 | $2.4B | $664.8M | ||
| Q4 24 | $2.5B | $729.4M | ||
| Q3 24 | $2.6B | $684.0M | ||
| Q2 24 | $2.6B | $691.7M | ||
| Q1 24 | $2.4B | $649.9M |
净利润GPNRVTY
| Q4 25 | $217.5M | $98.4M | ||
| Q3 25 | $635.2M | $46.7M | ||
| Q2 25 | $241.6M | $53.9M | ||
| Q1 25 | $305.7M | $42.2M | ||
| Q4 24 | $567.2M | $94.6M | ||
| Q3 24 | $315.1M | $94.4M | ||
| Q2 24 | $374.8M | $55.4M | ||
| Q1 24 | $313.3M | $26.0M |
毛利率GPNRVTY
| Q4 25 | 89.7% | — | ||
| Q3 25 | 72.3% | 53.6% | ||
| Q2 25 | 74.5% | 54.5% | ||
| Q1 25 | 61.8% | 56.5% | ||
| Q4 24 | 62.1% | — | ||
| Q3 24 | 63.6% | 56.3% | ||
| Q2 24 | 63.5% | 55.7% | ||
| Q1 24 | 61.9% | 54.6% |
营业利润率GPNRVTY
| Q4 25 | 5.9% | 14.5% | ||
| Q3 25 | 38.8% | 11.7% | ||
| Q2 25 | 21.8% | 12.6% | ||
| Q1 25 | 19.5% | 10.9% | ||
| Q4 24 | 33.1% | 16.3% | ||
| Q3 24 | 18.3% | 14.3% | ||
| Q2 24 | 22.3% | 12.4% | ||
| Q1 24 | 18.7% | 6.8% |
净利率GPNRVTY
| Q4 25 | 16.4% | 12.7% | ||
| Q3 25 | 31.6% | 6.7% | ||
| Q2 25 | 12.3% | 7.5% | ||
| Q1 25 | 12.7% | 6.4% | ||
| Q4 24 | 22.5% | 13.0% | ||
| Q3 24 | 12.1% | 13.8% | ||
| Q2 24 | 14.6% | 8.0% | ||
| Q1 24 | 12.9% | 4.0% |
每股收益（稀释后）GPNRVTY
| Q4 25 | $0.91 | $0.86 | ||
| Q3 25 | $2.64 | $0.40 | ||
| Q2 25 | $0.99 | $0.46 | ||
| Q1 25 | $1.24 | $0.35 | ||
| Q4 24 | $2.23 | $0.77 | ||
| Q3 24 | $1.24 | $0.77 | ||
| Q2 24 | $1.47 | $0.45 | ||
| Q1 24 | $1.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3B | $919.9M |
| 总债务越低越好 | $19.5B | — |
| 股东权益账面价值 | $22.9B | $7.3B |
| 总资产 | $53.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.85× | — |
8季度趋势，按日历期对齐
现金及短期投资GPNRVTY
| Q4 25 | $8.3B | $919.9M | ||
| Q3 25 | $2.6B | $931.4M | ||
| Q2 25 | $2.6B | $991.8M | ||
| Q1 25 | $2.9B | $1.1B | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.9B | $1.2B | ||
| Q2 24 | $2.1B | $2.0B | ||
| Q1 24 | $2.2B | $1.7B |
总债务GPNRVTY
| Q4 25 | $19.5B | — | ||
| Q3 25 | $13.3B | — | ||
| Q2 25 | $14.2B | — | ||
| Q1 25 | $15.0B | — | ||
| Q4 24 | $15.2B | — | ||
| Q3 24 | $15.2B | — | ||
| Q2 24 | $15.6B | — | ||
| Q1 24 | $15.6B | — |
股东权益GPNRVTY
| Q4 25 | $22.9B | $7.3B | ||
| Q3 25 | $22.7B | $7.4B | ||
| Q2 25 | $22.6B | $7.6B | ||
| Q1 25 | $22.2B | $7.6B | ||
| Q4 24 | $22.3B | $7.7B | ||
| Q3 24 | $22.8B | $7.9B | ||
| Q2 24 | $22.4B | $7.9B | ||
| Q1 24 | $22.2B | $7.8B |
总资产GPNRVTY
| Q4 25 | $53.3B | $12.2B | ||
| Q3 25 | $48.0B | $12.1B | ||
| Q2 25 | $48.5B | $12.4B | ||
| Q1 25 | $47.6B | $12.4B | ||
| Q4 24 | $46.9B | $12.4B | ||
| Q3 24 | $50.0B | $12.8B | ||
| Q2 24 | $50.8B | $13.4B | ||
| Q1 24 | $51.8B | $13.4B |
负债/权益比GPNRVTY
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $515.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $347.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 26.1% | 21.0% |
| 资本支出强度资本支出/营收 | 12.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.37× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.0B | $509.4M |
8季度趋势，按日历期对齐
经营现金流GPNRVTY
| Q4 25 | $515.2M | $182.0M | ||
| Q3 25 | $768.7M | $138.5M | ||
| Q2 25 | $817.5M | $134.3M | ||
| Q1 25 | $555.1M | $128.2M | ||
| Q4 24 | $653.4M | $174.2M | ||
| Q3 24 | $1.7B | $147.9M | ||
| Q2 24 | $736.9M | $158.6M | ||
| Q1 24 | $416.3M | $147.6M |
自由现金流GPNRVTY
| Q4 25 | $347.0M | $161.8M | ||
| Q3 25 | $598.9M | $120.0M | ||
| Q2 25 | $665.4M | $115.5M | ||
| Q1 25 | $427.5M | $112.2M | ||
| Q4 24 | $469.4M | $149.8M | ||
| Q3 24 | $1.6B | $125.6M | ||
| Q2 24 | $557.7M | $136.6M | ||
| Q1 24 | $270.9M | $129.7M |
自由现金流率GPNRVTY
| Q4 25 | 26.1% | 21.0% | ||
| Q3 25 | 29.8% | 17.2% | ||
| Q2 25 | 34.0% | 16.0% | ||
| Q1 25 | 17.7% | 16.9% | ||
| Q4 24 | 18.7% | 20.5% | ||
| Q3 24 | 60.0% | 18.4% | ||
| Q2 24 | 21.7% | 19.7% | ||
| Q1 24 | 11.2% | 20.0% |
资本支出强度GPNRVTY
| Q4 25 | 12.7% | 2.6% | ||
| Q3 25 | 8.5% | 2.6% | ||
| Q2 25 | 7.8% | 2.6% | ||
| Q1 25 | 5.3% | 2.4% | ||
| Q4 24 | 7.3% | 3.4% | ||
| Q3 24 | 6.4% | 3.3% | ||
| Q2 24 | 7.0% | 3.2% | ||
| Q1 24 | 6.0% | 2.7% |
现金转化率GPNRVTY
| Q4 25 | 2.37× | 1.85× | ||
| Q3 25 | 1.21× | 2.97× | ||
| Q2 25 | 3.38× | 2.49× | ||
| Q1 25 | 1.82× | 3.03× | ||
| Q4 24 | 1.15× | 1.84× | ||
| Q3 24 | 5.48× | 1.57× | ||
| Q2 24 | 1.97× | 2.87× | ||
| Q1 24 | 1.33× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GPN
| Integrated And Embedded Solutions | $869.3M | 65% |
| Point Of Sale And Software Solutions | $281.7M | 21% |
| Other | $178.4M | 13% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
